Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers-Reference-Cited by-同舟云学术

Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers

Published:2015-06 Issue:4 Volume:47 Page:341-348
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Feng Qin,Baker Susan S.,Liu Wensheng,Arbizu Ricardo A.,Aljomah Ghanim,Khatib Maan,Nugent Colleen A.,Baker Robert D.,Forte Trudy M.,Hu Yiyang,Zhu Lixin

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference51 articles.

1. The novel apolipoprotein A5 is presentin human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipo-proteins;O’Brien;Clin Chem,2005

2. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing;Pennacchio;Science,2001

3. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism;Lookene;J Biol Chem,2005

4. Intravenous injection of apoli-poprotein A-V reconstituted high-density lipoprotein decreases hypertri-glyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1;Shu;Arterioscler Thromb Vasc Biol,2010

5. ApoAV reduces plasma triglycer-ides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis;Schaap;J Biol Chem,2004

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters;Theranostics;2024

2. Role of apolipoproteins in the pathogenesis of obesity;Clinica Chimica Acta;2023-05

3. Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017–2018) and a controlled animal study;Nutrition & Metabolism;2022-12-13

4. Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights;Frontiers in Cardiovascular Medicine;2022-10-04

5. Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine;Frontiers in Pharmacology;2022-08-12